For investors willing to stomach volatility for a chance at explosive gains, some small and mid‑cap stocks are drawing attention on Wall Street. These companies operate in fast‑moving sectors, such as obesity drugs, crypto infrastructure, and autoimmune therapeutics, where breakthroughs can rapidly boost valuations. According to analysts, the following three stocks offer some of the most compelling high‑risk, high‑reward setups in the market right now.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Altimmune (ALT)
Altimmune’s lead candidate, pemvidutide, has shown promising mid‑stage data, including solid weight loss and potential metabolic benefits. If upcoming clinical milestones go well, Altimmune could become a real competitor in a category dominated by Novo Nordisk (NVO) and Eli Lilly (LLY).
The risks are still high. The company is in development mode, and late-stage obesity trials are difficult. But since obesity drugs are one of the biggest and fastest‑growing markets in healthcare, even a small share of the category could significantly boost the stock.
Recently, Truist analyst Srikripa Devarakonda initiated coverage of Altimmune stock with a Buy rating and a $12 price target. She believes the company’s lead drug, pemvidutide, could be effective in treating MASH and other liver‑related diseases. The analyst is modeling about 20,000 peak patients on pemvidutide, which would translate to roughly $600 million to $1 billion in worldwide peak revenue.
Turning to Wall Street, ALT stock has a Strong Buy consensus rating based on five Buys and one Hold assigned in the last three months. At $13.50, the average Altimmune stock price target implies upside potential of 378.72%.
Bit Digital (BTBT)
Bit Digital has shifted from being a pure Bitcoin miner to a broader digital infrastructure company with exposure to both crypto and AI. It now operates across Bitcoin mining, Ethereum staking, and AI compute hosting, giving it multiple paths for growth depending on where demand picks up. For investors seeking leveraged exposure to two major tech themes, Bit Digital offers significant upside potential.
Earlier this month, H.C. Wainwright’s Kevin Dede reiterated a Buy rating and $7 target, citing solid FY25 revenue, rising staking income, and growing WhiteFiber value. He also cited the company’s shift toward a “next‑gen” digital asset treasury model that he believes supports a valuation well above the current market cap.
Wall Street’s consensus rating for BTBT stock is Strong Buy based on three unanimous Buys. The average analyst price target of $4.50 implies an upside potential of 185.71% from current levels.
Kyverna Therapeutics (KYTX)
Kyverna Therapeutics is a new player in autoimmune cell therapy, and analysts see big upside if it can deliver on its clinical plans. Its lead therapy, KYV‑101, is being tested in conditions like lupus nephritis and multiple sclerosis, where current options often fall short.
The risks remain as early‑stage biotech is unpredictable, but if Kyverna’s data continues to look strong, the stock can climb sharply as the market begins to price in a new treatment category.
Morgan Stanley’s Michael Ulz reiterated a Buy rating and $33 target on Kyverna stock, citing strong Phase 2 miv‑cel data and FDA alignment on the Phase 3 design.
On TipRanks, analysts have a Strong Buy consensus rating on KYTX stock based on five Buys assigned in the past three months. Further, the average Kyverna price target of $29.00 per share implies 207.53% upside potential.
